Mucin 1 peptide-Major Histocompatibility Complex (MUC1-MHC)

Mucin 1 (MUC1) is a high-molecular-weight transmembrane glycoprotein normally expressed on the apical surface of ductal epithelial cells, where it provides lubrication and protection (Finn, O. J., 2003, Nature Reviews Immunology). In many adenocarcinomas, MUC1 is overexpressed, loses its polarized distribution, and undergoes aberrant glycosylation, which exposes peptide epitopes that are processed and presented by Major Histocompatibility Complex (MHC) Class I and Class II molecules (Beatty and Gladney, 2015, Clinical Cancer Research). These MUC1-MHC complexes are recognized by T-cell receptors (TCRs), making them critical targets for cancer immunotherapy. MHC Class I complexes typically activate CD8+ cytotoxic T lymphocytes, while MHC Class II complexes activate CD4+ helper T cells, both contributing to an anti-tumor immune response (Zhou et al., 2019, Journal of Hematology & Oncology). Therapeutic interventions targeting these complexes include peptide-based vaccines like Tecemotide, viral vector vaccines like TG4010, and TCR-engineered T-cell therapies designed to overcome the immunosuppressive tumor microenvironment. Because MUC1 is also present on normal tissues, the specificity of these therapies often relies on the differential glycosylation or significantly higher expression levels found in malignant versus healthy cells.

Other names

MUC1-HLA complexMUC1 peptide-MHC class I complexMUC1 peptide-MHC class II complexMucin 1-derived peptide-MHC complexpMHC MUC1

Induction of antigen-specific T-cell mediated cytotoxicity and cytokine production through the recognition of MUC1-derived peptides presented by MHC Class I and Class II molecules by T-cell receptors (TCRs).